Your browser is no longer supported. Please, upgrade your browser.
Settings
PPH VanEck Vectors Pharmaceutical ETF daily Stock Chart
PPH [NASD]
VanEck Vectors Pharmaceutical ETF
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand- Perf Week-5.12%
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month-5.73%
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-5.00%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio16.41 Perf Half Y-1.61%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year2.15%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range54.56 - 64.90 Perf YTD-0.07%
Dividend0.98 P/FCF- EPS past 5Y- ROI- 52W High-6.46% Beta-
Dividend %1.65% Quick Ratio- Sales past 5Y- Gross Margin- 52W Low11.27% ATR1.01
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)46.42 Volatility2.23% 1.44%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.84 Prev Close59.27
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume49.76K Price60.71
Recom- SMA20-1.17% SMA50-1.74% SMA2000.74% Volume54,015 Change2.43%
Dec-10-18 10:33AM  Dont Punish Gilead Stock for Doing Its Job InvestorPlace
Nov-16-18 05:52PM  VanEck Announces Preliminary Yearend Distribution Estimates for VanEck Vectors Equity ETFs Business Wire
Oct-24-18 11:59AM  ETF Strategies for the Midterm Elections Zacks
Oct-17-18 11:48AM  VanEck Launches ESPO, ETF Focused on Fast Growing Video Game and eSports Industry Business Wire
Oct-12-18 06:00AM  Top 5 Pharmaceutical ETFs for 2018 Investopedia
Oct-09-18 11:39AM  Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)? Zacks
Sep-28-18 06:03PM  Announcing VanEck Vectors Equity ETFs September 2018 Distributions Business Wire
Jul-03-18 03:19PM  July Could Be a Volatile Month for Pharma ETFs ETF Trends
Jun-29-18 06:15PM  Announcing VanEck Vectors Equity ETFs June 2018 Distributions Business Wire
Jun-04-18 10:38AM  Biogen Inc Stock Got an Upgrade, but Should You Listen? InvestorPlace
Apr-24-18 06:41AM  Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)? Zacks
Mar-29-18 05:58PM  Announcing VanEck Vectors Equity ETFs March 2018 Distributions Business Wire
Jan-25-18 09:00AM  Tasigna Could Boost Novartiss Revenue Growth in 2018 Market Realist
07:31AM  Novartis Receives 2 Breakthrough Therapy Designations in January Market Realist
Jan-22-18 10:00AM  Behind Novartiss 4Q17 Earnings: Why Some Expect Revenue Growth Market Realist
07:34AM  Johnson & Johnsons Consumer Segment: 4Q17 Estimates Market Realist
Jan-15-18 10:31AM  How Teva Pharmaceutical Is Realigning Organizational Structure Market Realist
Jan-10-18 12:03PM  Mylans Valuation in January 2018 Market Realist
Jan-09-18 10:31AM  Valeant on the Street: Analyst Recommendations in December 2017 Market Realist
Jan-08-18 07:33AM  How Did Novo Nordisks NovoMix and Human Insulin Perform in 2017? Market Realist
Jan-05-18 10:35AM  How Novo Nordisks Biopharmaceuticals Segment Performed in 3Q17 Market Realist
Dec-26-17 06:15PM  Announcing VanEck Vectors Equity ETFs December 2017 Distributions Business Wire
Nov-22-17 05:30PM  VanEck Announces Preliminary Yearend Distribution Estimates for VanEck Vectors Equity ETFs Business Wire
Nov-14-17 02:35PM  Understanding Sanofis Revenues by Segment in 3Q17 Market Realist
Oct-16-17 12:33PM  President Trump reiterates that drug companies 'getting away with murder' but says not much else MarketWatch
Oct-02-17 12:35PM  CORRECTING and REPLACING Announcing VanEck Vectors Equity ETFs September 2017 Distributions Business Wire
Sep-29-17 05:25PM  Announcing VanEck Vectors Equity ETFs September 2017 Distributions Business Wire
Sep-20-17 10:36AM  Why Cosentyx Could Significantly Drive Novartiss Revenue Growth Market Realist
Sep-19-17 10:38AM  An Update on Novartiss Sandostatin, Afinitor, and Exjade Market Realist
Sep-14-17 07:39AM  TEVA Depends on This for Revenue Growth Market Realist
Sep-11-17 10:36AM  How Mercks Gardasil and Other Human Vaccines Performed in 2Q17 Market Realist
07:36AM  Where Jazz Pharmaceuticals Erwinaze and Prialt Are Positioned after 2Q17 Market Realist
Sep-06-17 09:06AM  Performance of AstraZenecas Other Products in 2Q17 Market Realist
Sep-05-17 07:37AM  Performance of AstraZenecas Growth Platforms in 2Q17 Market Realist
Sep-04-17 09:06AM  Performance of Eli Lillys Neuroscience Products in 2Q17 Market Realist
Aug-31-17 12:34PM  Changes in GlaxoSmithKlines Valuation after 2Q17 Market Realist
07:38AM  How Novartiss Sandoz Performed in 2Q17 Market Realist
Aug-30-17 07:36AM  Johnson & Johnsons Medical Devices Segment in 2Q17 Market Realist
Aug-23-17 11:53AM  JAZZ Is Focused on Increasing Market Adoption of Defitelio Market Realist
09:53AM  Jazz Pharmaceuticals Is Focused on Label Expansion of Defitelio Market Realist
Aug-21-17 04:05PM  Inside Jazzs Net Profit Margin Expectations for 2017 Market Realist
Aug-17-17 07:37AM  Sanofis Revenue Growth in 2Q17 Market Realist
Aug-15-17 09:06AM  Pfizers Important Product Developments in 2Q17 Market Realist
Aug-14-17 10:25AM  Why Vertex Pharmaceuticals Incorporated (VRTX) Stock Isnt Worth the Risk InvestorPlace
Aug-07-17 09:53AM  How Valeant Pharmaceuticals Intl Inc (VRX) Stock Can Make a Comeback InvestorPlace
Aug-01-17 11:21AM  Buy Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Before Q2 Earnings InvestorPlace
07:41AM  GlaxoSmithKlines 2Q17 Earnings: Business Segments Market Realist
Jul-31-17 06:05PM  Bristol-Myers Squibbs 2Q17 Earnings: Opdivo Market Realist
Jul-28-17 05:05PM  Eli Lilly in 2Q17: Performance of New Products Market Realist
Jul-27-17 07:44AM  Analysts Recommendations for AstraZeneca in 2Q17 Market Realist
Jul-25-17 04:25PM  Inside GlaxoSmithKlines 2Q17 Earnings Estimates Market Realist
Jul-24-17 01:05PM  Foreign Exchange Impacts Novartiss Growth in 2Q17 Market Realist
10:37AM  Johnson & Johnson: Consumer Products in 2Q17 Market Realist
Jul-17-17 10:39AM  Analysts Latest Recommendations for Johnson & Johnson Market Realist
10:27AM  Novartiss 2Q17 Earnings: Analyst Estimates Market Realist
Jul-11-17 09:07AM  Farxiga Could See Robust Demand in International Markets in 2017 Market Realist
Jul-10-17 03:10PM  What Lies Ahead for Pharma ETFs in Second Half 2017 Zacks
07:39AM  What We Can Expect from Eli Lilly and Company in 2Q17 Market Realist
Jul-04-17 10:37AM  Johnson & Johnsons Pharmaceuticals Business in 1Q17 Market Realist
07:36AM  Keytrudas Developments in June 2017 Market Realist
Jul-03-17 09:10AM  AstraZeneca May Witness a Fall in 2017 Net Profit Margin Market Realist
Jun-30-17 05:27PM  Announcing VanEck Vectors Equity ETFs June 2017 Distributions Business Wire
Jun-28-17 10:36AM  Pfizers Profitability in 1Q17 Market Realist
Jun-21-17 09:08AM  Analyzing Bristol-Myers Squibbs Valuation on June 20 Market Realist
Jun-20-17 12:09PM  SK Biotek to Acquire Manufacturing Facility in Swords, Ireland Market Realist
Jun-08-17 09:06AM  What Drove Pfizer in 1Q17? Market Realist
Jun-02-17 07:36AM  Inside Novartiss Generics Business Now Market Realist
Jun-01-17 10:37AM  GlaxoSmithKlines Consumer Healthcare Segment in 1Q17 Market Realist
May-24-17 09:06AM  Gardasil and Mercks Vaccines Business in 1Q17 Market Realist
May-18-17 09:07AM  Behind Bristol-Myers Squibbs 1Q17 Performance Market Realist
May-09-17 09:06AM  Comparing Pfizers Valuation to Peers after 1Q17 Earnings Market Realist
May-02-17 10:36AM  How GlaxoSmithKlines Consumer Healthcare Segment Fared in 1Q17 Market Realist
07:38AM  Analyzing GlaxoSmithKlines Global Pharmaceutical Performance Market Realist
May-01-17 07:39AM  Eli Lillys 1Q17 Earnings: Humalog and Other Endocrine Products Market Realist
Apr-28-17 09:08AM  1Q17 Earnings for Novartiss Alcon, Its Eye Care Business Market Realist
Apr-27-17 09:08AM  Dupixent Expected to Be a Solid Addition to Regenerons Portfolio Market Realist
Apr-26-17 12:05PM  What Analysts Recommend for AstraZeneca Market Realist
10:37AM  A Look at Bristol-Myers Squibbs Other Segments in 1Q17 Market Realist
Apr-24-17 09:07AM  Novartiss 1Q17 Estimates for Alcon Market Realist
Apr-21-17 03:05PM  Analysts Expect Novartiss Revenues to Remain Flat in 1Q17 Market Realist
10:36AM  Eli Lillys Estimate for Strattera, Other Neuroscience Products Market Realist
Apr-17-17 12:17PM  5 ETFs to Buy If You Love Johnson & Johnson's First-Quarter Earnings TheStreet.com
Apr-14-17 07:37AM  Analyzing Johnson & Johnsons Medical Devices Segment Market Realist
Apr-04-17 09:06AM  Is Sanofi Pasteur Living Up to Its Name? Market Realist
09:06AM  Is Sanofi Pasteur Living Up to Its Name?
Apr-03-17 10:39AM  What Have Clinical Trials of Novartiss LEE011 Demonstrated? Market Realist
10:39AM  What Have Clinical Trials of Novartiss LEE011 Demonstrated?
09:07AM  The Latest from Sanofis Diabetes and Cardiovascular Franchise Market Realist
09:07AM  The Latest from Sanofis Diabetes and Cardiovascular Franchise
07:36AM  Novartis Is Focused on Creating Shareholder Value in 2017 Market Realist
07:36AM  Novartis Is Focused on Creating Shareholder Value in 2017
Mar-31-17 06:16PM  Announcing VanEck Vectors Equity ETF's March 2017 Distributions Business Wire
09:06AM  How Eli Lillys Neuroscience Franchises 2016 Turned Out Market Realist
09:06AM  How Eli Lillys Neuroscience Franchises 2016 Turned Out
Mar-30-17 09:06AM  GlaxoSmithKlines Consumer Healthcare Segment in 2016 Market Realist
09:06AM  GlaxoSmithKlines Consumer Healthcare Segment in 2016
Mar-29-17 10:36AM  Cosentyx Enjoys Solid Demand as Psoriasis Therapy in Europe Market Realist
10:36AM  Cosentyx Enjoys Solid Demand as Psoriasis Therapy in Europe
09:06AM  Performance of Key Pharmaceuticals Products for GlaxoSmithKline Market Realist
09:06AM  Performance of Key Pharmaceuticals Products for GlaxoSmithKline
The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.